NCT00440544View on ClinicalTrials.gov

A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

February 29, 2008

Conditions
Tuberculosis
Interventions
BIOLOGICAL

Ag85B-ESAT6 fusion protein H1

100 ug H1 antigen in BCG naive subjects

BIOLOGICAL

Ag85B-ESAT6 fusion protein H1

100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects

BIOLOGICAL

Ag85B-ESAT6 fusion protein H1

50 ug H1 antigen in BCG immunized subjects

BIOLOGICAL

Ag85B-ESAT6 fusion protein H1

50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects

BIOLOGICAL

Ag85B-ESAT6 fusion protein H1

100 ug H1 antigen in BCG immunized subjects

BIOLOGICAL

Ag85B-ESAT6 fusion protein H1

100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects

Trial Locations (1)

SW17 0RE

St George's Vaccine Institute, London

Sponsors

Collaborators (1)

Novartis Vaccines
All Listed Sponsors
collaborator

Statens Serum Institut

OTHER

collaborator

Novartis Vaccines

INDUSTRY

collaborator

European Union

OTHER

lead

St George's, University of London

OTHER